Opening Question Is microdosing psychedelics the breakthrough wellness trend that supporters claim, or are we getting ahead of the science? As millions of people around the world experiment with tiny doses of LSD and psilocybin mushrooms, researchers are racing to understand whether these practices actually...
Opening Question Could psilocybin therapy offer hope for people with bipolar 2 depression who have been excluded from most psychedelic research due to safety concerns? A groundbreaking new study suggests that psilocybin-assisted therapy might be both safe and effective for this underserved population, potentially opening...
Opening Question Could a nasal spray be the breakthrough that millions of people with treatment-resistant depression have been waiting for? The FDA's recent approval of Spravato (esketamine) as a standalone treatment marks a historic moment in mental health care—but what do the clinical trial results...
What question is this article answering? What are the most effective, evidence-based treatment protocols for managing psychedelic-induced psychosis and HPPD (Hallucinogen Persisting Perception Disorder), and how can clinicians safely help patients who experience persistent adverse effects from psychedelic use? Synopsis: Recent clinical research has identified...